Nanotechnology Now

Our NanoNews Digest Sponsors


Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > BioNanomatrix Secures $23.3 Million in Series B Financing: Domain Associates leads round for genomics company; Battelle Ventures, Gund Investment Corp., Innovation Valley Partners and KT Venture Group participate

Abstract:
BioNanomatrix, Inc., a developer of nanoscale, single-molecule imaging and analysis platforms designed to dramatically reduce the time and cost needed to analyze the genome, has closed a $23.3-million Series B round of equity financing.

BioNanomatrix Secures $23.3 Million in Series B Financing: Domain Associates leads round for genomics company; Battelle Ventures, Gund Investment Corp., Innovation Valley Partners and KT Venture Group participate

Philadelphia, PA | Posted on March 18th, 2011

Domain Associates, based in Princeton, N.J., and San Diego, Calif., led the round, with new investor Gund Investment Corporation and existing investors Battelle Ventures, Innovation Valley Partners and KT Venture Group joining the round.

"The Series B financing comes at a pivotal time for the company, as we advance toward commercialization of our unique nanoAnalyzer platform for whole genome analysis," said R. Erik Holmlin, newly elected president and chief executive officer of BioNanomatrix.

Holmlin noted that BioNanomatrix introduced the nanoAnalyzer 1000 System at the 2010 annual meeting of the American Society of Human Genetics last November and said that the company "has already placed a number of systems with early-access users."

"BioNanomatrix has made impressive progress in developing and refining its platform technology and testing the nanoAnalyzer in collaboration with leading researchers in the genomics field," said Domain Associates Partner Brian K. Halak, PhD., who joins the company's Board of Directors.

"This capital infusion enables BioNanomatrix to establish a strong West Coast presence that will provide additional business opportunities and the ability to recruit from a talent base that has established this industry," Dr. Halak continued.

"Looking ahead," he said, "we are confident that the affordability, speed and simplicity of the nanoAnalyzer technology will make the routine use of genetic information feasible in broad-ranging applications, including molecular diagnostics, personalized medicine and biomedical research."

####

About BioNanomatrix, Inc.
Named in 2010 as one of 50 companies to watch by Medical Device and Diagnostic Industry, BioNanomatrix is developing and commercializing technologies for analysis of large biological molecules, such as nucleic acids, which are vital to life science research, clinical diagnostic applications and development of new therapeutics. This technology is designed to dramatically reduce the time and complexity to analyze the genome and provide additional information, including structural variation data, which is not easily addressed with current methods. The company’s products will provide users with the means to perform single-molecule analyses on minute biological samples that are essentially unattainable, too impractical or too costly to achieve using current technology. The company’s current development efforts include a NIST-ATP-funded project to sequence the human genome at a cost of $100, as well as support from the National Institutes of Health.

Note: BioNanomatrix and nanoAnalyzer are trademarks of BioNanomatrix, Inc. Any other names of actual companies, organizations, entities, products or services may be the trademarks of their respective owners.

For more information, please click here

Contacts:
Rick Sacks
973-467-8728

Copyright © Business Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Hybrid nanoantennas -- next-generation platform for ultradense data recording April 28th, 2016

Superfast light source made from artificial atom April 28th, 2016

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521 April 28th, 2016

The Translational Research Center at the University Hospital of Erlangen in Germany uses the ZetaView from Particle Metrix to quantify extracellular vesicles such as exosomes April 28th, 2016

JPK reports on the use of a NanoWizard AFM system at the University of Kaiserslautern to study the interaction of bacteria with microstructured surfaces April 28th, 2016

Imaging

The Translational Research Center at the University Hospital of Erlangen in Germany uses the ZetaView from Particle Metrix to quantify extracellular vesicles such as exosomes April 28th, 2016

JPK reports on the use of a NanoWizard AFM system at the University of Kaiserslautern to study the interaction of bacteria with microstructured surfaces April 28th, 2016

Bruker Introduces First of Its Kind Dimensional Analysis System: The Novel Contour CMM™ System Fully Integrates 3D Coordinate Measurements with Nanoscale Surface Height, Texture, Waviness and Form Characterization April 26th, 2016

Bruker Introduces Dimension FastScan Pro Industrial AFM: Providing Nanometer-Resolution at High Scan Rates for up to 300-mm Samples April 26th, 2016

XEI Scientific and the University of Southern California collaborate on the use of downstream plasma cleaning in sample preparation and publish a paper in ACS Photonics April 26th, 2016

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

ORIG3N Added to Companies Presenting at Harris & Harris Group's Annual Meeting, Tuesday June 7, 2016, the New York Genome Center April 27th, 2016

Investments/IPO's/Splits

ORIG3N Added to Companies Presenting at Harris & Harris Group's Annual Meeting, Tuesday June 7, 2016, the New York Genome Center April 27th, 2016

Aspen Aerogels to Present at the 28th Annual ROTH Conference March 14th, 2016

Harris & Harris Group Announces Formation of Co-Investment Fund for Accredited Investors March 9th, 2016

Arrowhead to Present at Upcoming March Conferences March 1st, 2016

Announcements

Hybrid nanoantennas -- next-generation platform for ultradense data recording April 28th, 2016

Superfast light source made from artificial atom April 28th, 2016

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521 April 28th, 2016

The Translational Research Center at the University Hospital of Erlangen in Germany uses the ZetaView from Particle Metrix to quantify extracellular vesicles such as exosomes April 28th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic